Abiomed's Impella 2.5 enters new US trial
This article was originally published in Clinica
A new clinical trial of Abiomed's Impella 2.5 circulatory support system is set to begin in the US following conditional FDA approval of the study protocol. The Impella device, already approved in Canada and CE marked in the EU, is inserted into the left ventricle in a minimally-invasive procedure, and helps pump blood in heart failure patients.
You may also be interested in...
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.